sponsored
PatientsVille.com Logo

PatientsVille

Macular Degeneration Medical Research Studies

Up-to-date List of Macular Degeneration Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Macular Degeneration Medical Research Studies

Rank Status Study
1 Recruiting Complement Factor H Haplotypes and Smoking in Age-related MACULAR DEGENERATION
Condition: Macular Degeneration
Intervention:
Outcome Measures: Assessment of Age-related Macular Degeneration;   Visual field test;   OCT;   Fluorescein Angiography;   assessment of smoking status;   Eye exam with fundus photography;   genotyping for signal nucleotide polymorphisms for I62V and Y402H in CFH gene;   Complement pathway protein analysis
2 Recruiting S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related MACULAR DEGENERATION in Men on SELECT SWOG-S0000
Conditions: Cataract;   Macular Degeneration
Interventions: Drug: selenium;   Drug: vitamin E;   Drug: vitamin E placebo;   Drug: selenium placebo
Outcome Measures: Visually significant age-related MACULAR DEGENERATION (AMD);   Cataract with best corrected visual-acuity of 20/30;   Advanced AMD;   Cataract extraction
3 Recruiting Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related MACULAR DEGENERATION
Condition: Age Related Macular Degeneration
Interventions: Device: Telescope prosthesis;   Device: WA-NG Telescope Prothesis
Outcome Measure: Safety
4 Recruiting OZURDEX in Age Related MACULAR DEGENERATION as Adjunct to Ranibizumab
Condition: Wet Macular Degeneration
Interventions: Drug: Ranibizumab;   Drug: OZURDEX
Outcome Measures: Gains in visual acuity;   Changes in intraocular pressure;   Rates of re-treatment;   Rate of vision loss;   Rate of cataract progression;   Changes in choroid vessel activity in lesion growth and activity at choroid
5 Unknown  Sub-tenon Triamcinolone Acetonide in Age-Related MACULAR DEGENERATION as Adjunct to Ranibizumab
Condition: Wet Macular Degeneration
Interventions: Drug: Ranibizumab;   Drug: Triamcinolone Acetonide
Outcome Measures: Gains in visual acuity;   Changes in intra-ocular pressure;   Rates of re-treatment;   Rate of vision loss;   Rate of cataract progression;   • Changes in choroid vessel activity in lesion growth and activity at choroid
6 Recruiting Laser Intervention in Early Age-Related MACULAR DEGENERATION Study
Condition: Age-related Macular Degeneration
Intervention: Device: 2RT nanosecond laser
Outcome Measures: progression to advanced Age-related MACULAR DEGENERATION (AMD) in the treated eye;   progression to advanced AMD  in the untreated eye
7 Recruiting Evaluation of Wet Age-Related MACULAR DEGENERATION (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes
Condition: Age Related Macular Degeneration
Intervention: Drug: Ranibizumab
Outcome Measures: Gains in visual acuity;   Changes in choroid vessel activity in lesion growth and activity at choroid;   Rate of cataract progression;   Resolution of macular edema;   Mean change in visual acuity according to identified genetic mutations;   Mean change in visual acuity regardless of genetic profile results;   Interaction of smoking status and genetic profile on visual acuity changes
8 Recruiting Prophylactic Ranibizumab for Exudative Age-related MACULAR DEGENERATION
Condition: Age-related Macular Degeneration
Intervention: Drug: Ranibizumab 0.5mg
Outcome Measures: Development of exudative AMD;   Vision change;   Vision loss;   Number of injections;   Baseline predictive factors;   Development of geographic atrophy (GA);   Ocular adverse events;   Systemic adverse events
9 Unknown  Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related MACULAR DEGENERATION
Condition: Macular Degeneration
Interventions: Drug: Microplasmin;   Drug: Placebo control
Outcome Measures: The primary outcome is the proportion of patients in whom there is release of vitreomacular traction as assessed by ultrasonography, optical coherence tomography and physical examination;   Total number of ranibizumab injections following microplasmin in those with PVD compared with those without PVD;   Change in mean macular thickness;   Mean change in ETDRS visual acuity;   Incidence and severity of ocular adverse events;   Incidence and severity of nonocular adverse events
10 Not yet recruiting A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related MACULAR DEGENERATION (DRAW).
Condition: Neovascular Macular Degeneration
Intervention: Drug: Aflibercept
Outcome Measures: Pharmacokinetic (PK) aflibercept aqueous;   PK Aflibercept plasma
11 Unknown  Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related MACULAR DEGENERATION (AMD)
Condition: Macular Degeneration
Interventions: Drug: ORA102 and Avastin;   Drug: Avastin
Outcome Measures: The incidence and severity of ocular adverse events, including retinal detachment, increase in IOP, cataract, tearing of the retina, decrease in vision, RPE atrophy, and vitreous hemorrhage, will be evaluated.;   Central Retinal thickness and presence of intra/sub-retinal fluid observed by OCT at week 32
12 Recruiting Proton Radiation Therapy for MACULAR DEGENERATION
Condition: Age-Related Macular Degeneration
Intervention: Radiation: Proton radiation
Outcome Measures: Number of participants with acute and late morbidity of the eye as a measure of safety;   Number of participants with cessation of growth of neovascular membranes.;   Visual acuity per comprehensive eye exam;   Frequency of intravitreal injections following radiation treatment
13 Recruiting Neovascular Age-related MACULAR DEGENERATION
Condition: Neovascular Age-related Macular Degeneration
Intervention:
Outcome Measure: Number of patients with NVAMD receiving treatment who also have changed retinal/choroidal anatomy and/or blood flow compared to treatment naive NVAMD patients
14 Unknown  Safety Study for Treatment of Wet MACULAR DEGENERATION Using the TheraSight(TM) Ocular Brachytherapy System
Conditions: Macular Degeneration;   Choroidal Neovascularization
Intervention: Device: Ocular Brachytherapy
Outcome Measures: Incidence of serious adverse events 30 to 270 days after treatment;   Serious adverse events occurring 9 months to 3 years after treatment;   Reported adverse events occurring at any time after treatment;   Feasibility of device use based on physician interviews and ultrasonography;   Observation of retinal and angiographic appearance of CNV lesion and best-corrected visual acuity
15 Recruiting Study of Dark Adaptation in Age-Related MACULAR DEGENERATION
Condition: Age-Related Macular Degeneration
Intervention:
Outcome Measures: The primary outcome is to determine mean change, including the distribution of change, in dark adaptation response;   The primary outcome is to determine mean change, including the distribution of change, in dark adaptation response between baseline and months 12 and 24 for Groups 0 - 3.;   The mean change in dark adaptation response;   Mean BCVA change;   The exploratory outcomes are to correlate mean BCVA with mean dark adaptation response and AMD severity with dark adaptation response;   The secondary outcomes are the mean change in dark adaptation response and mean BCVA change from baseline at all time points.
16 Recruiting Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related MACULAR DEGENERATION
Condition: Macular Degeneration
Interventions: Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506);   Procedure: Sham IVT;   Drug: Ranibizumab;   Drug: Placebo
Outcome Measures: Change in BCVA (Best corrected visual acuity) from baseline to week 4 for study part A;   Change in BCVA from baseline to week 12 for study part A;   Change in BCVA from baseline to week 4 for study part B;   Change in BCVA from baseline to week 12 for study part B;   Proportion of subjects with individual changes in BCVA of ≥ 0 letters of vision for study part A;   Proportion of subjects with a loss of ≥ 10 letters for study part A;   Proportion of subjects with individual changes in BCVA of ≥ 0 letters of vision for study part B;   Proportion of subjects with a loss of ≥ 10 letters for study part B
17 Not yet recruiting Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related MACULAR DEGENERATION
Condition: Wet Age-related Macular Degeneration
Interventions: Drug: Bevacizumab;   Drug: Ranibizumab
Outcome Measures: • Proportion of patients losing fewer than 15 letters on EDTRS chart at month 12;   • Frequency of ocular and systemic adverse events (AE) and serious adverse events (SAE) that are related, in Investigator's opinion, to AMD therapy;   • Frequency of AE and SAE with toxicity level of 3-4 that are related, in Investigator's opinion, to AMD therapy;   • Number of cases of early withdrawal from the study caused by AE or SAE;   • Number of patients who have binding and neutralizing antibodies to BCD-021/Lucentis in serum at screening and month 12;   • The mean titer of binding and neutralizing antibodies to BCD-021/Lucentis in serum at screening and month 12;   • Mean change in VA score, measured on the EDTRS scale at month 12;   • Average number of injections and time before re-injection;   • Lesion size at month 6 and month 12 (by angiography);   •       Lesion leakage at month 6 and month 12;   • Change in fluid and foveal thickness on OCT during the study;   • Retinal sensitivity measured by microperimetry at screening, at month 6 and month 12;   • Timing of visual improvement after initiation of therapy
18 Recruiting Brain Connectivity in Age-Related MACULAR DEGENERATION
Condition: Age-Related Macular Degeneration
Intervention:
Outcome Measure: Cognitive Changes and Brain Connectivity in Age-Related MACULAR DEGENERATION
19 Unknown  Subretinal Macugen® for Neovascular Age-Related MACULAR DEGENERATION
Condition: Age-related Macular Degeneration
Intervention: Drug: Pegaptanib (Macugen®)
Outcome Measures: Proportion of patients who had lost fewer than 15 letters of visual acuity at 54 weeks;   Mean change from baseline in total size of lesion and total size of CNV at 12, 24 and 54 weeks;   Changes in best corrected visual acuity (BCVA) from baseline at 54 weeks;   Mean change from baseline in at week 12 and 24;   Proportion of patients who gain ≥ 5, 10, 15 letters of BCVA from baseline at week 24 and 54;   Proportion of patients who lose less than 15 letters of BCVA from baseline at week 24 and 54;   Change in area of leakage at 12, 24 and 54 weeks;   Mean change in retinal thickness by OCT at center of fovea at 12, 24 and 54 weeks
20 Unknown  Intravitreal Bevacizumab for Age-Related MACULAR DEGENERATION
Condition: Age Related Macular Degeneration
Intervention: Drug: bevacizumab intravitreal injection
Outcome Measures: Improvement of visual acuity at 6 months;   Retinal thickness at 6 months;   Leakiness in fluorangiography at 6 months

These studies may lead to new treatments and are adding insight into Macular Degeneration etiology and treatment.

A major focus of Macular Degeneration research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Macular Degeneration